Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique

NCT01697007 is registered in ClinicalTrials.gov with Muhimbili University of Health and Allied Sciences as lead sponsor.

NCT NCT01697007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01697007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique
Lead sponsor
Muhimbili University of Health and Allied Sciences
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2012
Completion date
June 30, 2015
Enrollment
198 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, immunogenicity, safety, vaccines